Skip to content
type1.science
ObservationalRecruitingNCT07118098

INNODIA DETECT: family and friends autoantibody screening

What this study tests

Recruiting European observational screening protocol testing islet autoantibodies in children and adults aged 1–45 who have a relative or close friend diagnosed with T1D before age 45. It finds people at risk; it is not a treatment trial. Estimated enrolment 30,000.

Editorial review: .

Registry checked: 2026-09-17. Registry’s own update: 2026-08-24.

Most recent recorded citation date: 2026-08-24. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Evidence at a glance

Who can enter the study?
Ages 1–45 with a family relative or close friend diagnosed with symptomatic T1D before age 45. People already diagnosed with stage 3 T1D or other diabetes are excluded. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
Reported benefit and results
No results. Recruiting; estimated n=30,000; actual start 25 June 2025; estimated primary completion December 2027. Last registry update 24 August 2026. Sites include Austria, Belgium, Czechia, France, Germany, Italy, Slovenia, and Poland (not yet recruiting).Read the result sources and their limitations →
Important harms
Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
Research access and approval
Study regions: European Union. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
What remains uncertain?
Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.

Research status alone does not establish approval, clinical benefit or local availability.

Primary endpoints

  • Presence of one or more T1D islet autoantibodies by end of 2027

The full picture

INNODIA DETECT is a large relatives-and-friends autoantibody screen. A negative test ends the protocol; a confirmed positive is meant to move people into a separate INNODIA MONITOR follow-up, which is not this record.

Sources

  1. [1]